Fingolimod granted FDA Breakthrough Therapy designation...

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Fingolimod granted FDA Breakthrough Therapy designation...

Postby MSUK » Tue Dec 19, 2017 6:47 am

Fingolimod granted FDA Breakthrough Therapy designation for paediatric MS

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple sclerosis (MS)...Read more - http://www.ms-uk.org/fingolimod-granted-fda-breakthrough-therapy-designation-paediatric-ms

Image
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2887
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service